STOCK TITAN

Ekso Bionics Holdings (EKSO) Stock News, Jan-Jun 2024

EKSO Nasdaq

Ekso Bionics Holdings Inc. news has covered its exoskeleton technology business for medical and industrial applications, including robotic systems designed to support mobility, strength, endurance, and rehabilitation. Company updates include financial results, product and distribution activity, sales trends for Enterprise Health devices and Ekso Indego Personal devices, and rehabilitation offerings such as MediTouch’s BalanceTutor system and eksoUniversity continuing education courses.

Recurring corporate developments also include material agreements, shareholder voting matters, capital-structure disclosures, governance actions, and the completed formation of ChronoScale through a strategic combination involving EKSO Bionics.

Rhea-AI Summary

Ekso Bionics has appointed Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. Scher brings extensive healthcare experience, having served as an Executive Advisor to the U.S. Department of Veterans Affairs (VA). She led the VA Secretary's Center for Strategic Partnerships and implemented over $250 million in programs for veterans. Currently, she is a Senior Advisor at the Milken Institute and serves on multiple boards. Scher's appointment aligns with Ekso's recent Medicare reimbursement pricing for the Ekso Indego Personal, which aids in patient rehabilitation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
management
-
Rhea-AI Summary

Ekso Bionics Holdings, an industry leader in exoskeleton technology, will feature the Ekso Indego Personal on 'Health Uncensored' with Dr. Drew Pinsky on Fox Business News. The episode will air on May 12, showcasing the device's user-reported benefits and advanced technology. The Ekso Indego Personal is a powered exoskeleton designed to help patients with mobility impairments walk independently, offering a potentially life-changing solution for individuals previously confined to wheelchairs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
-
Rhea-AI Summary

Ekso Bionics reported financial results for the first quarter of 2024, highlighting revenues of $3.8 million and a gross margin of 52%. The company achieved a final payment determination for Medicare reimbursement, sold 29 EksoHealth units, and focused on developing the market for Indego Personal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.88%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.76%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences earnings
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags

FAQ

What is the current stock price of Ekso Bionics Holdings (EKSO)?

Ekso Bionics Holdings (EKSO) last closed at $11.8.

What is the market cap of Ekso Bionics Holdings (EKSO)?

The market cap of Ekso Bionics Holdings (EKSO) is approximately $42.0M.